is there still a glp-1 shortage GLP-1s Going Direct, How Novo and Lilly's DTC Strategy Changing the Game for Patients and Plan Sponsors FDA restricts non-approved compounded GLP-1

Emerging evidence suggests beneficial effects of GLP-1RAs on inflammatory diseases, including cutaneous disorders [4, 5]

Injectable side effects are injection side effects: small bumps or redness at the site, rare mild headache, theoretically some systemic effects at higher doses

Arroyo-Hernandez M, Maldonado F, Lozano-Ruiz F, Munoz-Montano W, Nunez-Baez M, Arrieta O

Therapeutic Optionality and Pipeline Catalysts Beyond obesity, the GLP-1 drug class has evolved into a broader platform for metabolic and longevity-related therapies

Ozempic persistence among obesity users was 35% at the 12 month mark

Accordingly, we included patients treated with at least two other glucose-lowering agents (GLAs) at the baseline period, reflecting the common use at Israel at the time